market is driven by the rising prevalence of diabetes, the growing demand for self-monitoring of blood glucose levels, and advancements in technology.

Medical technology manufacturer plans to divest diabetes products business / Focus on injection systems © 2001-2024 Plasteurope.com | Imprint | Privacy | Cookie settings ...

Switzerland is scrambling to keep a lid on immigration from its top trade partner, the European Union, as a jobs boom powered ...

Switzerland is scrambling to keep a lid on immigration from its top trade partner, the European Union, as a jobs boom powered ...

Advancements in medical technology and increasing awareness about diabetes and blood testing drive innovation and adoption in the lancet industry.

The latest health news highlights FDA's approval of BridgeBio's drug for a rare heart condition, cancer features in healthy ...

智通财经获悉，知情人士透露，诺和诺德(NVO.US)与瑞士医疗器械制造商Ypsomed 签订合同，Ypsomed ...

High-yielding stocks can be due for cuts to their payouts if a company's underlying financials aren't strong enough to ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish ...

The Jefferies London Healthcare Conference at Waldorf Hilton drew thousands, focusing heavily on GLP-1 manufacturing. Notable ...